

CLINICAL—LIVER

High-Dose Pegylated Interferon- α and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With *IL-28B* Genotype (SYREN Trial)

STÉPHANE CHEVALIEZ,^{*,†} CHRISTOPHE HÉZODE,^{*,§} ALEXANDRE SOULIER,^{*,‡} BRUNO COSTES,^{‡,||} MAGALI BOUVIER-ALIAS,^{*,‡} STÉPHANIE ROUANET,[¶] JULIETTE FOUCHER,[#] JEAN-PIERRE BRONOWICKI,^{**} ALBERT TRAN,^{††} ISABELLE ROSA,^{§§} PHILIPPE MATHURIN,^{|||} LAURENT ALRIC,^{¶¶} VINCENT LEROY,^{##} PATRICE COUZIGOU,[#] ARIANE MALLAT,^{*,‡} MARIEM CHARAF-EDDINE,[¶] GÉRARD BABANY,[¶] and JEAN-MICHEL PAWLOTSKY^{*,‡}

^{*}National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil; [§]Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Université Paris-Est, Créteil; [†]Department of Biochemistry, Hôpital Henri Mondor, Université Paris-Est, Créteil; [‡]Roche, Neuilly-sur-Seine; [¶]Department of Hepatology and Gastroenterology, Hôpital Haut-Lévêque, Université Victor Segalen Bordeaux 2, Pessac; ^{**}Department of Hepatology and Gastroenterology, INSERM U954, Centre Hospitalier Universitaire, Université Henri Poincaré, Vandœuvre-les-Nancy; ^{††}Department of Hepatology and Gastroenterology, Hôpital de l'Archet, Université de Nice, Nice; ^{§§}Department of Hepatology and Gastroenterology, Centre Hospitalier Intercommunal, Créteil; ^{|||}Department of Hepatology and Gastroenterology, Hôpital Claude Huriez, Université de Lille, Lille; ^{¶¶}Department of Internal Medicine, Hôpital Purpan, Université de Toulouse, Toulouse; ^{##}Department of Hepatology and Gastroenterology, Hôpital de la Tronche, Université de Grenoble, Grenoble, France

This article has an accompanying continuing education activity on [page e18](#). Learning Objective: Upon completion of this CME exercise, successful learners will be able to integrate the predictors of response to antiviral therapy based on pegylated IFN- and ribavirin in patients infected with hepatitis C virus genotype 1 and apply these concepts to novel combination therapies with pegylated IFN-, ribavirin and a protease inhibitor.

BACKGROUND & AIMS: In patients with chronic hepatitis C who failed to respond to standard therapy, high-dose pegylated interferon (IFN)- α and/or ribavirin could induce a stronger antiviral response and prevent treatment failure and HCV resistance when combined with direct-acting antivirals. The influence of genetic determinants in this context remains unknown. **METHODS:** Eighty-three patients infected with HCV genotype 1 who were nonresponsive to standard therapy received pegylated IFN- α 2a (360 μ g once per week or 180 μ g twice per week) with ribavirin (1.0–1.2 or 1.2–1.6 g/d) for up to 72 weeks. Virological responses were assessed at different time points, and the influence of the *IL-28B* genotype was studied. **RESULTS:** At weeks 12 and 24, respectively, 47 (56.6%) and 50 (60.2%) patients achieved a ≥ 2 -Log₁₀ decrease of HCV RNA levels; 8 (9.6%) and 21 (25.3%) patients had undetectable HCV RNA after 12 and 24 weeks of treatment, respectively. Patients with a CT *IL-28B* genotype responded significantly better and earlier than those with a TT genotype. In multivariate analysis, the *IL-28B* genotype was an independent predictor of the virological responses at weeks 4, 12, and 24. **CONCLUSIONS:** High-dose pegylated IFN- α with standard or high doses of ribavirin induces a potent antiviral response in a substantial number of patients who did not respond to standard therapy. The *IL-28B* genotype is an independent predictor of the antiviral response. High-dose pegylated IFN- α in combination with ribavirin and protease inhibitors appears as an attractive option for future study in this population.

Keywords: Hepatitis C Virus; Nonresponder; High-Dose Pegylated IFN- α ; *IL-28B* Genotype.

Hepatitis C virus (HCV) chronically infects approximately 120–130 million individuals worldwide.¹ Chronic HCV infection is a major cause of life-threatening liver disease, and approximately 20% of HCV-infected patients develop cirrhosis.² Indeed, HCV infection is the main indication for liver transplantation and is becoming the leading cause of hepatocellular carcinoma in industrialized areas.² Mortality related to HCV infection has been estimated at approximately 300,000 deaths per year.

HCV infection is curable by therapy. Current treatment is based on a combination of pegylated interferon (IFN)- α and ribavirin. In patients infected with HCV genotype 1, by far the most frequent HCV genotype worldwide, only 40% to 50% of such treatment led to a cure of infection.^{3–5} Failure of IFN- α -based treatments to eradicate HCV infection has been recently shown, at least partly, to be genetically determined. Single nucleotide polymorphisms (SNPs) in the region upstream of the *IL-28B* (IFN- λ 3) gene in chromosome 19 have been identified to be strongly associated with the ability of pegylated IFN- α and ribavirin to cure HCV infection.^{6–8} The underlying mechanisms remain obscure.

In 2011, new treatments will be available for chronic HCV genotype 1 infection. They will be based on a combination of pegylated IFN- α , ribavirin, and a specific HCV protease inhibitor, telaprevir or boceprevir. Phase II and

Abbreviations used in this paper: BMI, body mass index; IFN, interferon; SNP, single nucleotide polymorphism; SVR, sustained virological response.

© 2011 by the AGA Institute
0016-5085/\$36.00
doi:10.1053/j.gastro.2011.03.039

III clinical trials have shown that approximately 25%–35% of treatment-naïve patients, and 50%–60% of those who have previously failed on pegylated IFN- α and ribavirin alone, fail to eradicate HCV on such triple combination.^{9–17} Treatment failure is principally due to an insufficient antiviral response to pegylated IFN- α and ribavirin, favoring the outgrowth of protease inhibitor resistant viruses selected by the direct acting antiviral agent.^{10,12,13,18} Therefore, a sufficient antiviral response to pegylated IFN- α and ribavirin is an absolute prerequisite to achieve cure of infection with new triple combination therapies without selecting for resistant viruses.

Because recent reports indicated that the outcomes of triple combinations with pegylated IFN- α , ribavirin, and an HCV protease inhibitor strongly depend on the ability of IFN- α and ribavirin to substantially reduce HCV replication,^{10,12,13,18} which has recently been shown to be strongly associated with *IL-28B* polymorphisms,^{6–8,19,20} we decided to assess the ability of high doses of pegylated IFN- α with standard or high doses of ribavirin to induce a significant antiviral response in genotype 1 patients who failed to respond to a first course of therapy at standard doses and whether responsiveness to high-dose pegylated IFN- α and ribavirin is genetically driven in this population.

Methods

Patients

The SYREN trial (ClinicalTrials.gov number NCT00412334) is a phase II randomized, open-labeled clinical trial that included 104 patients infected with HCV genotype 1. These patients were previously treated with the standard combination of pegylated IFN- α 2a (180 μ g per week) and ribavirin (1.0–1.2 g/d according to body weight), received at least 80% of the treatment dose during the first 12 weeks of therapy, and did not achieve a ≥ 2 -Log₁₀ decrease of HCV RNA levels between baseline and week 12 of treatment (the same HCV RNA assay was used at both time points).

Inclusion criteria were male or female patient 18 years of age or older; evidence of chronic HCV infection (positive anti-HCV antibody and detectable HCV RNA); HCV genotype 1; normal or elevated serum alanine aminotransferase level; compensated liver disease; liver fibrosis assessment by means of a noninvasive serological or elastographic test within 12 months before inclusion; negative pregnancy test for women of childbearing age at inclusion; efficacious double contraception (patient and partner) on treatment and 6 months thereafter; health insurance coverage; and written informed consent. At least 4 weeks without treatment were required before inclusion.

Exclusion criteria included current pregnancy or breastfeeding; male partner of a pregnant women; decompensated liver disease; hepatocellular carcinoma; human immunodeficiency virus, hepatitis A virus or hepatitis B virus co-infection; any other cause of liver disease; previous history of autoimmune disease, chronic lung disease, se-

vere heart disease, organ transplantation, cancer; hemoglobin level <12 g/dL (women) or <13 g/dL (men); patient at increased risk of anemia or for whom anemia could be a vital risk; neutropenia <1500 cells/mm³; thrombocytopenia <75,000/mm³; creatininemia >1.5 times the upper limit of normal values; patient who withdrew from earlier pegylated IFN- α 2a and ribavirin treatment for hematological adverse events; previous history of allergy to experimental drugs or to one of their components; any antiviral, antineoplastic or immunomodulatory treatment within 6 months before inclusion, except pegylated IFN- α 2a and ribavirin; active drug abuse or current chronic alcoholism; previous history of severe psychiatric disease; current treatment with anticonvulsants; thyroid disorder not controlled by medication; severe retinopathy or eye disorder related to diabetes or hypertension; poorly controlled high blood pressure; and previous history or risk of vein thrombosis.

The goal of the SYREN trial was to evaluate the efficacy and safety of 4 intensified regimens of pegylated IFN- α 2a and ribavirin in this population. The patients were randomized to receive pegylated IFN- α 2a, either 360 μ g once per week or 180 μ g twice per week, in combination with ribavirin, either 1.0–1.2 g/d or 1.2–1.6 g/d according to body weight, for the full duration of therapy. As per the protocol stopping rules, treatment was halted at weeks 12 or 24 in patients with a <0.5- or <2.0-Log₁₀ drop of HCV RNA levels, respectively, or if HCV RNA was still detectable at week 48. The planned treatment duration in the remaining patients was initially 48 weeks. An amendment was passed to prolong therapy for a total of 72 weeks at the same doses of pegylated IFN- α and ribavirin in patients who had undetectable HCV RNA at week 48 of therapy. The study was approved by an Institutional Review Board (Comité de Protection des Personnes, Hôpital Henri Mondor, Créteil, France).

All of the analyses have been performed on the intent-to-treat population, which included 98 nonresponder patients who received at least 1 dose of study drug and had at least 1 HCV RNA measurement under treatment. After the report of a relationship between *IL-28B* genotype and the response to IFN- α -based therapy, another amendment was passed in order to allow us to test the patients for *IL-28B* genotype. Eighty-three of the 98 patients gave their informed consent to the genetic testing and constitute the study population of this article. The baseline characteristics of the patients who did not give their informed consent did not differ from those in the study patients. As no significant differences in virological response rates were observed between the treatment groups at different time points, the patients from the 4 groups were considered together in this study.

HCV RNA Level Monitoring

HCV RNA levels were measured at baseline and at weeks 1, 2, 4, 12, 24, 48, and 72 hours of therapy. In the patients receiving 72 weeks of therapy, HCV RNA levels

were also measured at week 96, ie, 24 weeks after the end of treatment. The COBAS AmpliPrep/COBAS TaqMan automated real-time polymerase chain reaction (PCR) platform (Roche Molecular Systems, Pleasanton, CA) was used. This assay has a lower limit of detection of 15 IU/mL and a lower limit of quantification of 43 IU/mL.²¹ The sustained virological response (SVR) was defined as an undetectable HCV RNA 24 weeks after the end of therapy; the SVR corresponds to a cure of infection in >99% of cases.²²

IL-28B Polymorphism (rs12979860) Determination

IL-28B genotype at SNP position rs12979860 was determined by means of an original real-time PCR method using genomic DNA extracted from frozen serum samples in conjunction with minor groove binder probes. Briefly, free circulating nucleic acids were extracted from 400 μ L serum by means of the QIAasymphony DNA Midi kit (Qiagen GmbH, Hilden, Germany) on the QIAasymphony SP automated extractor. rs12979860 genotyping was performed by means of real-time PCR in the TaqMan Gene Expression Master Mix on the ABI 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA), with the following primers and probes: reverse primer: 5'-GAGCGCGGAGTGCAATTC-3'; forward primer: 5'-TGCCTGTGCTGTACTGAA-3'; VIC-probe: 5'-TCCCCGAAGGCGTGA-3'; FAM-probe: 5'-AAGGCGCGAACCA-3'. Automated allele calling was performed by means of Sequence Detection System software version 1.4 (Applied Biosystems).

Statistical Analysis

Statistical analysis was performed with SAS 9.1 software (SAS Institute Inc, Cary, NC). Tests were 2-sided and a type I error was set at .05. Missing data were not replaced. The week 1 virological response was calculated between treatment start and day 7 of therapy. The second-phase slope was computed by linear regression using HCV RNA levels at days 8 and 28 of therapy. Comparisons between IL-28B genotypes (CT vs TT) were performed using χ^2 test or Fisher exact test for qualitative variables, and Student *t* test or Wilcoxon test for continuous variables.

The relationship between the virological responses at different time points and explanatory variables was analyzed by logistic regression. The variables were selected by univariate logistic regression among age, sex, IL-28B polymorphisms, body mass index (BMI), duration of HCV infection, source of HCV infection, cirrhosis, subtype of HCV genotype, HCV RNA level changes during the first course of treatment, duration of the first course of treatment, baseline HCV RNA level, alanine aminotransferase level and γ -glutamyl transferase activity, number of pegylated IFN- α injections per week, and daily ribavirin dose. Significant variables after univariate regression analysis were entered into a stepwise multivariate model. Results are expressed as odds ratios with 95% confidence intervals.

The positive and negative predictive values, sensitivities, and specificities of the IL-28B genotypes for the virological responses at different time points were calculated.

Role of the Funding Source

This study is investigator-initiated. It has been sponsored by Roche (Neuilly-sur-Seine, France). Roche also provided medication and support for statistical analysis.

Results

Characteristics of the Study Patients

Table 1 shows the characteristics of the 83 patients who gave their consent for the IL-28B analysis. All of them had undergone a first course of therapy with standard doses of pegylated IFN- α 2a and ribavirin, had received >80% of the pegylated IFN- α 2a and ribavirin dose, and had stopped therapy at week 12 because they failed to achieve a >2 Log₁₀ HCV RNA level drop. They were retreated with high-dose pegylated IFN- α combined with standard- or high-dose ribavirin. No significant differences (and no trend toward differences) in virological responses were observed between the 4 treatment groups (either 360 μ g once per week or 180 μ g twice per week of pegylated IFN- α , combined with a standard or a high dose of ribavirin) at different time points. In particular, there was no influence of a standard or high dose of ribavirin on virological outcomes (data not shown). Thus, the patients from the 4 groups were pooled together for analysis to assess the virological response to retreatment with a high dose of pegylated IFN- α (with a standard or high dose of ribavirin) and the influence of the IL-28B genotype on this response. Figure 1 shows a flow chart of patient disposition in the trial. The following results are based on intent-to-treat analysis.

Only 3 patients had a CC genotype at IL-28B SNP position rs12979860. Their characteristics at baseline did not differ from those in the remaining patients. Two of them did not achieve a 2-Log₁₀ HCV RNA decline and stopped therapy at week 24 as per the protocol stopping rule; the third one responded but failed to achieve an SVR. The CC patients were thus removed from the analysis to allow for comparison of the 55 (66.3%) CT and the 25 (30.1%) TT patients. The characteristics of the patients did not differ between these 2 groups. In particular, there was no significant difference in the mean HCV RNA levels at baseline ($P = .76$) (Table 1).

Virological Response to High-Dose Pegylated IFN- α With Ribavirin

At week 12, 48 of the 83 patients (57.8%) who had not responded to a standard treatment dose (<2 -Log₁₀ HCV RNA level drop) achieved a ≥ 2 -Log₁₀ HCV RNA level drop and 8 (9.6%) had undetectable HCV RNA (<15 IU/mL). At week 24, 51 patients (61.4%) achieved a ≥ 2 -Log₁₀ HCV RNA level drop and 21 (25.3%) had undetectable HCV RNA.

Table 1. Baseline Characteristics of Patients According to the *IL-28B* Genotype (TT, CT, and CC at SNP position rs12979860)

Characteristics	All patients	TT	CT	CC
n	83	25	55	3
Males, n (%)	57 (68.7)	13 (52.0)	41 (74.5)	3 (100)
Age (y), median (range)	50 (34–68)	49 (34–66)	50 (37–68)	52 (47–59)
First course of therapy				
First treatment duration (wk), mean $\pm$ SD	28.4 $\pm$ 4.0	28.7 $\pm$ 13	28.0 $\pm$ 14.5	33.6 $\pm$ 7.8
Baseline HCV RNA level (Log_{10} IU/mL), mean $\pm$ SD	6.1 $\pm$ 0.8	6.3 $\pm$ 0.6	6.1 $\pm$ 0.8	6.0 $\pm$ 0.4
HCV RNA level at week 12 (Log_{10} IU/mL), mean $\pm$ SD	5.2 $\pm$ 0.9	5.4 $\pm$ 0.7	5.1 $\pm$ 1.0	5.2 $\pm$ 0.9
BMI, ^a median (range)	25.6 (18.5–39.5)	25.1 (20.3–37.6)	25.7 (18.5–39.5)	25.3 (24.8–36.8)
BMI $\geq$ 25, n (%)	46/77 (59.7)	11/22 (50.0)	33/52 (63.5)	2/3 (66.7)
BMI $\geq$ 30, n (%)	13/77 (16.9)	2/22 (9.1)	10/52 (19.2)	1/3 (33.3)
Cirrhosis, ^b n (%)	37 (44.6)	11 (44.0)	24 (43.6)	2 (66.7)
HCV genotype 1 subtype, ^c n (%)				
1a	35 (42.2)	12 (48.0)	23 (41.8)	0 (0.0)
1b	44 (53.0)	12 (48.0)	30 (54.5)	2 (66.7)
Other ^d	4 (4.8)	1 (4.0)	2 (3.6)	1 (33.3)
Baseline ALT level (IU/mL), median (range)	98 (16–554)	109 (27–440)	81 (16–554)	103 (41–166)
Baseline HCV RNA level (Log_{10} IU/mL), mean $\pm$ SD	6.5 $\pm$ 0.6	6.5 $\pm$ 0.6	6.5 $\pm$ 0.5	6.4 $\pm$ 0.1
Baseline HCV RNA level $>800,000$ IU/mL, n (%)	70 (84.3)	21 (84.0)	46 (83.6)	3 (100.0)
Treatment received				
PegIFN 360 qw + ribavirin standard dose	21 (25.3)	5 (20.0)	16 (29.1)	0 (0)
PegIFN 180 biw + ribavirin standard dose	22 (26.5)	8 (32.0)	14 (25.5)	0 (0)
PegIFN 360 qw + ribavirin high dose	18 (21.7)	5 (20.0)	12 (21.8)	1 (33.3)
PegIFN 180 biw + ribavirin high dose	22 (26.5)	7 (28.0)	13 (23.6)	2 (66.7)

ALT, alanine aminotransferase; biw, twice per week; qw, once per week; SD, standard deviation.

^aBMI is the weight in kilograms divided by the square of the height in meters; BMI was available in 77 patients only, including 22 TT, 52 CT, and 3 CC patients.

^bCirrhosis was diagnosed by means of liver biopsy in 6 patients and noninvasive tests, including Fibrotest and/or Fibroscan in the remaining cases.

^cHCV genotype and subtype were determined by means of direct sequence analysis of a portion of the HCV nonstructural 5B gene followed by phylogenetic analysis.

^dOther HCV subtypes were subtype 1i in 1 patient with a CC genotype, 1h and indeterminate in 2 patients with a CT genotype, and 1i in one patient with a TT genotype.

Due to a high incidence of post-treatment relapses, only 5 patients (6.0%) achieved an SVR. HCV RNA was undetectable at week 12 of therapy in all of them, and already at week 4 in 1 of them. Only 1 of the 5 patients who achieved an SVR had received the full 72 weeks of therapy, the remaining 4 having discontinued earlier due to adverse events or patient or investigator decision.

Week 12 Virological Response to Retreatment With High-Dose Pegylated IFN- α With Ribavirin According to the *IL-28B* Genotype

At week 12 of retreatment with high-dose pegylated IFN- α with standard- or high-dose ribavirin, the mean $\pm$ standard deviation Log_{10} HCV RNA level decrease was significantly greater than during the first course of therapy with a standard dose of pegylated IFN- α and ribavirin in both patients with a CC and a TT *IL-28B* genotype: -2.78 ± 1.59 vs -1.04 ± 0.55 ($P < .0001$), and -1.72 ± 0.90 vs -0.86 ± 0.65 ($P = .0015$), respectively.

Kinetics of Virological Response to High-Dose Pegylated IFN- α With Ribavirin According to the *IL-28B* Genotype

As shown in Figure 2 and in Table 2, patients with a CT genotype responded significantly better (and earlier) to high-dose pegylated IFN- α and ribavirin than those with a TT genotype. Indeed, the proportions of CT patients with a >0.5 , 1.0, or 2.0 Log_{10} HCV RNA decrease were significantly higher than those in TT patients at weeks 2, 4, and 12–24, respectively. At weeks 24, 48, and at week 72 (end of treatment in patients who had undetectable HCV RNA at week 48), the proportion of patients with an undetectable HCV RNA was significantly higher in the CT patients than in the TT patients. The 5 patients who achieved an SVR were all in the CT group (9.1% vs 0%, not significant).

As shown in Figure 2, the average HCV RNA decline during the first 7 days of therapy, which combines both first- and second-phase HCV RNA declines, was slightly but not significantly greater in CT than in TT patients (-0.35 ± 0.49 vs -0.24 ± 0.34 Log_{10} IU/mL, respectively; $P = .33$). In




Figure 1. Flow chart of patient disposition. "Other" causes of treatment interruption include patient's decision (n = 4), investigator's decision (n = 3), and death unrelated to the study drugs (n = 1).

contrast, the average weekly HCV RNA decline between days 8 and 28 of therapy, which accurately measures the second-phase decline, was significantly greater in CT than in TT patients (-0.28 ± 0.17 vs -0.18 ± 0.12 Log₁₀ IU/mL/week, respectively; $P = .004$).

Predictors of Virological Responses to High-Dose Pegylated IFN- α and Ribavirin

As shown in Table 3, the IL-28B genotype was an independent predictor of the virological response at all tested time points, with CT patients being significantly more likely to respond than TT patients. Other predictors of response included female sex, BMI (paradoxically, bigger patients responded better to high-dose therapy), ab-

sence of cirrhosis, a >0.5 Log₁₀ HCV RNA decrease during the first course of therapy with standard doses of pegylated IFN- α and ribavirin, and a low HCV RNA level at baseline (Table 3).

Predictive Value of the IL-28B Genotype on Virological Responses to High-Dose Pegylated IFN- α and Ribavirin

Table 4 shows the positive and negative predictive values, sensitivities, and specificities of the IL-28B genotype for the virological responses to high-dose pegylated IFN- α and ribavirin at weeks 4, 12, and 24.

Adverse Events

Every patient experienced at least one adverse event during the study period; 23 of them (27.7%) experienced at least 1 severe adverse event. Treatment discontinuation due to an adverse event or to a severe adverse event has been observed in 11 (13.3%) and 6 (7.2%) patients, respectively. Table 5 shows the most frequent ($\geq 10\%$) adverse events observed in the 83 patients during the trial. In contrast with a recent observation in patients receiving a standard dose of pegylated IFN- α and ribavirin,²³ no significant difference was observed between CT and TT patients (data not shown).

Discussion

In this study, patients chronically infected with HCV genotype 1 who failed to respond to a standard dose of pegylated IFN- α and ribavirin by a >2 -Log₁₀ HCV RNA level drop were retreated with a high dose of pegylated IFN- α 2a and a standard or high dose of ribavirin. High-dose pegylated IFN- α 2a was administered for the full duration of therapy, which was extended to 72 weeks if




Figure 2. Mean $\pm$ standard deviation (SD) HCV RNA level reductions from baseline in patients with a CT genotype (black circles) or a TT genotype (black squares). As a comparator, mean $\pm$ SD HCV RNA level reductions at week 12 of an earlier course of therapy with standard doses of pegylated IFN- α and ribavirin in the same patients are shown as dotted lines. P values are for CT vs TT patients.

Table 2. Proportions of Patients Who Achieved Different Magnitudes of HCV RNA Level Decline at Different Time Points During and After Treatment With High-Dose Pegylated IFN- α and Ribavirin According to the *IL28B* SNP rs12979860 Genotype (TT vs CT); Intent-to-Treat Analysis

Treatment week	rs12979860 (<i>IL28B</i>) genotype	n	Failure ^a n (%)	HCV RNA level reduction ≥ 0.5 Log ₁₀		HCV RNA level reduction ≥ 1.0 Log ₁₀		HCV RNA level reduction ≥ 2.0 Log ₁₀		Undetectable HCV RNA (<15 IU/mL)	
				n (%)	P value	n (%)	P value	n (%)	P value	n (%)	P value
Week 1	TT	24	NA	5 (20.8)	NS	0 (0)	NS	0 (0)	NS	0 (0)	NS
	CT	52		16 (30.8)		5 (9.6)		1 (1.9)		0 (0)	
Week 2	TT	25	NA	9 (36.0)	.02	4 (16.0)	NS	0 (0)	NS	0 (0)	NS
	CT	54		35 (64.8)		11 (20.4)		1 (1.9)		0 (0)	
Week 4	TT	25	NA	17 (68.0)	NS	7 (28.0)	.008	0 (0)	NS	0 (0)	NS
	CT	55		44 (80.0)		33 (60.0)		6 (10.9)		1 (1.8)	
Week 12	TT	25	1 (4.0)	23 (92.0)	NS	17 (68.0)	NS	10 (40.0)	.02	0 (0)	.05
	CT	55	0 (0)	50 (90.9)		45 (81.8)		37 (67.3)		8 (14.5)	
Week 24	TT	25	4 (16.0)	20 (80.0)	NS	16 (64.0)	NS	11 (44.0)	.02	3 (12.0)	.05
	CT	55	7 (12.7)	48 (87.3)		41 (74.5)		39 (70.9)		18 (32.7)	
Week 48	TT	25	NA	NA	NA	NA	NA	NA	NA	5 (20.0)	.04
	CT	55								24 (43.6)	
Week 72	TT	25	NA	NA	NA	NA	NA	NA	NA	2 (8.0)	.03
	CT	55								17 (30.9)	
Week 96	TT	25	NA	NA	NA	NA	NA	NA	NA	0 (0)	NS
	CT	55								5 (9.1)	

NOTE. P values are for comparison between CT and TT patients. n Values vary with the availability of the information at each time point. NA, not applicable as per the protocol.

^aAccording to the protocol stopping rules, ie, <0.5 Log₁₀ HCV RNA decline at week 12 or <2.0 Log₁₀ decline at week 24.

HCV RNA was undetectable at week 48. In this respect, the design of the trial was original, as formerly published retreatment trials used either standard doses of pegylated IFN- α and ribavirin for the full treatment course or short-term induction with high-dose pegylated IFN- α at the beginning of therapy.^{24–27} These studies generally also included patients who responded by a >2-Log₁₀ HCV RNA level drop at week 12, but subsequently failed to achieve an SVR during the first course of therapy. Despite these differences, only 5 patients in this trial (6%) achieved an SVR, all of them belonging to the CT group.

An important finding in this study was that in patients who were not able to achieve a 2.0 Log₁₀ drop of HCV

RNA levels at week 12 of treatment with standard doses of pegylated IFN- α and ribavirin, the use of a high dose of pegylated IFN- α 2a induced a substantial antiviral response at weeks 12 and 24 (≥ 2.0 Log₁₀ HCV RNA level reduction) in more than half of cases, with approximately one-quarter of the patients achieving undetectable HCV RNA at week 24. Although our study was not powered to assess this hypothesis, the lack of any trend toward a difference between the 4 treatment arms, and between the patients who received a standard and a high dose of ribavirin, suggests that the high dose of pegylated IFN- α 2a used was responsible for the significantly greater antiviral efficacy observed, regardless of pegylated IFN- α

Table 3. Predictors of HCV RNA Level Reduction Relative to Baseline at Different Time Points in Multivariate Analysis

Time point	HCV RNA level reduction	Predictors	Odds ratio (95% CI)	P value
Week 4	≥ 1.0 Log ₁₀	Sex (female vs male)	7.30 (1.85–28.57)	.005
		<i>IL28B</i> genotype (CT vs TT)	6.46 (1.77–23.54)	.005
		Week 12 HCV RNA decrease during the first course of therapy (≥ 0.5 Log ₁₀ vs <0.5 Log ₁₀)	5.76 (1.34–24.78)	.019
Week 12	≥ 2.0 Log ₁₀	Cirrhosis (absence vs presence)	3.67 (1.24–10.83)	.019
		BMI (≥ 26 vs <26)	4.31 (1.44–12.92)	.009
		<i>IL28B</i> genotype (CT vs TT)	3.30 (1.11–9.83)	.032
Week 24	≥ 2.0 Log ₁₀	BMI (≥ 26 vs <26)	2.82 (1.00–7.95)	.050
		<i>IL28B</i> genotype (CT vs TT)	3.72 (1.26–10.99)	.017
		Baseline HCV RNA level (<6 Log ₁₀ vs ≥ 6 Log ₁₀)	4.64 (0.90–23.84)	.066
Week 24	Undetectable ^a	Sex (female vs male)	8.62 (2.35–31.25)	.001
		<i>IL28B</i> genotype (CT vs TT)	9.12 (1.77–46.89)	.008
		Baseline HCV RNA level (<6 Log ₁₀ vs ≥ 6 Log ₁₀)	3.66 (0.92–14.49)	.066

NOTE. Parameters found to be associated with the HCV RNA level decrease at the specific time point with a P value $\geq .10$ in univariate analysis were included in the multivariate analysis.

CI, confidence interval.

^aUndetectable means <15 IU/mL.

Table 4. Positive and Negative Predictive Values, Sensitivities and Specificities of the *IL-28B* Genotype on the Virological Responses to High-Dose Pegylated IFN- α and Ribavirin at Weeks 4, 12, and 24

<i>IL-28B</i> polymorphism	Time point	HCV RNA level reduction	PPV (%)	NPV (%)	Sensitivity (%)	Specificity (%)
TT	Week 4	$\geq 1.0 \text{ Log}_{10}$	28.0	40.0	17.5	55.0
	Week 12	$\geq 2.0 \text{ Log}_{10}$	40.0	32.7	21.3	54.5
	Week 24	$\geq 2.0 \text{ Log}_{10}$	44.0	29.1	22.0	53.3
	Week 24	Undetectable	12.0	67.3	14.3	62.7
CT	Week 4	$\geq 1.0 \text{ Log}_{10}$	60.0	72.0	82.5	45.0
	Week 12	$\geq 2.0 \text{ Log}_{10}$	67.3	60.0	78.7	45.5
	Week 24	$\geq 2.0 \text{ Log}_{10}$	70.9	56.0	78.0	46.7
	Week 24	Undetectable	32.7	88.0	85.7	37.3

NPV, negative predictive value; PPV, positive predictive value.

frequency of administration (once or twice a week) and of the ribavirin dose administered. However, a marginal role for the latter could not be ruled out by our analysis and would require further analyses in larger groups of patients.

The present study also demonstrates that the ability of high-dose pegylated IFN- α with a standard or high dose of ribavirin to induce a significant antiviral response in earlier nonresponders to standard doses is under the influence of genetic determinants. Indeed, both patients with a CT and a TT genotype at SNP position rs12979860 responded significantly better to retreatment with high-dose pegylated IFN- α than to the first course of therapy with standard-dose pegylated IFN- α . Nevertheless, patients with a CT genotype responded significantly better, and earlier, to high-dose retreatment than patients with a TT genotype (Figure 2). These findings are in keeping with recent reports showing that, in treatment-naïve pa-

tients infected with HCV genotype 1, CT patients respond better than TT patients to standard doses of pegylated IFN- α and ribavirin.^{6–8,19,20} Interestingly, CT patients had less favorable baseline parameters, such as a higher BMI and a higher proportion of males (not significant), than TT patients, further emphasizing the importance of the genetic background of the host in the response to IFN- α .

A recent study assessing frequent viral kinetics in treatment-naïve patients receiving standard doses of pegylated IFN- α and ribavirin has shown nearly identical early viral kinetics among CT and TT patients.²⁸ CC patients, who achieve the highest rates of viral clearance, had a significantly steeper first-phase HCV RNA level decline than both CT and TT patients, while their second-phase slopes were not different.²⁸ This suggested that the *IL-28B* genotype essentially influences the ability of the patients to mount a potent direct antiviral response against HCV in response to IFN- α . Our data suggest that, when higher doses of pegylated IFN- α are used, CT patients respond significantly better than TT patients. In addition, the maximum effect of the *IL-28B* genotype in our study was on the second-phase decline, which measures the progressive clearance of infected cells. High doses of pegylated IFN- α could trigger antiviral mechanisms that are not involved when standard doses are used, and/or the lower level of “resistance” of cells from CT patients to the action of IFN could allow them to respond when exposure is increased.

Our sampling schedule did not allow us to study the first-phase decline in our patients. We cannot rule out a role for a difference between CT and TT patients in the first-phase decline that would ultimately influence the second-phase decline. Indeed, in patients who are naturally poorly responsive to IFN- α and ribavirin, a modest reduction of HCV RNA levels below a threshold that triggers infected cell clearance (or cure?) could have visible consequences on the second-phase decline only. These hypotheses will be difficult to verify unless appropriate experimental models are available and the molecular mechanisms underlying the relationship between *IL-28B* polymorphisms and HCV response to IFN- α -based therapy are unraveled.

Overall, our data suggest that high-dose pegylated IFN- α , in combination with a standard or a high dose of

Table 5. Principal Adverse Events ($\geq 10\%$) in the 83 Patients Included in the Study

Adverse event	Number of patients with the adverse event	% of patients with the adverse event
Asthenia	62	74.7
Anemia	44	53.0
Influenza-like illness	37	44.6
Neutropenia	31	37.3
Thrombocytopenia	27	32.5
Pruritus	25	30.1
Insomnia	22	26.5
Anger	22	26.5
Headache	20	24.1
Nausea	20	24.1
Cough	19	22.9
Dry skin	19	22.9
Dyspnea	18	21.7
Diarrhea	16	19.3
Sleep disorder	15	18.1
Leukopenia	14	16.9
Anorexia	11	13.3
Decreased appetite	11	13.3
Eczema	10	12.0
Myalgia	10	12.0
Back pain	10	12.0
Depression	9	10.8
Alopecia	9	10.8

ribavirin, is an interesting option for combination with telaprevir or boceprevir in order to minimize the risk of resistance selection and increase the SVR rates in nonresponders to earlier standard therapy. This is reinforced by the fact that these treatments would be given for 24 to 48 weeks, and the antiviral effect was sustained over this duration in our study in patients who responded. The minimal antiviral effect of pegylated IFN- α and ribavirin to achieve a high cure rate is still unknown. Phase II and III trials with pegylated IFN- α 2b, ribavirin, and boceprevir, which included a lead-in phase with pegylated IFN- α 2b and ribavirin alone, suggested that it could be of the order of 1.0-1.5 Log₁₀ IU/mL at week 4.^{10,15,16} Results from the REALIZE Trial with pegylated IFN- α 2a, ribavirin, and telaprevir, which included a lead-in phase with pegylated IFN- α 2a and ribavirin alone, also suggest a threshold at 1.0 Log₁₀ IU/mL at week 4.

Although the *IL-28B* genotype is a strong, independent predictor of the ability of high-dose pegylated IFN- α and ribavirin to induce an antiviral response in nonresponders, the individual predictive value of this marker was not very high in our study. Specifically, a substantial number of TT patients were able to achieve a significant antiviral response on treatment. Therefore *IL-28B* genotyping should not be recommended as a tool to deny high-dose pegylated IFN- α and ribavirin therapy in nonresponders retreated with a triple combination. Nevertheless, nonresponder CT patients represent an ideal population for this strategy. Stratification on the *IL-28B* genotype should therefore be recommended in future trials assessing strategies based on high-dose pegylated IFN- α and ribavirin.

Other predictors of response at different time points included female sex, absence of cirrhosis, a >0.5 Log₁₀ HCV RNA decline during the first course of therapy at standard doses and a low baseline HCV RNA level, parameters known to be associated with better SVR rates in HCV-infected patients.³⁻⁵ The noted effects of increased BMI appeared paradoxical, as bigger patients had a better response at weeks 12 and 24. This could be explained by the fact that higher doses work particularly well in patients in whom the principal cause of failure was a high BMI, responsible for insufficient IFN- α exposure during the first treatment course.

In conclusion, this study shows that high-dose pegylated IFN- α with standard or high doses of ribavirin is able to induce a potent antiviral response in a substantial number of patients who did not respond or responded poorly to a standard dose regimen. Patients with a CT *IL-28B* genotype respond significantly better and earlier to high-dose pegylated IFN- α and ribavirin than those with a TT genotype. High-dose pegylated IFN- α and ribavirin, therefore, appears to be a viable option to optimize HCV clearance rates in patients who failed on standard therapy and are retreated with a triple combination of pegylated IFN- α , ribavirin, and a protease inhibitor. This option, along with the ideal treatment schedule (our results suggest that high-dose pegylated IFN- α 2a should be admin-

istered once weekly, but the question remains open for pegylated IFN- α 2b, which bears different pharmacokinetic properties), should now be studied in prospective clinical trials according to the *IL-28B* genotype.

References

1. Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. *J Clin Pharmacol* 2004;44:20-29.
2. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006;45:529-538.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975-982.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004;140:346-355.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358:958-965.
6. Ge D, Fellay J, Thompson AJ, Simon JS, et al. Genetic variation in *IL28B* predicts hepatitis C treatment-induced viral clearance. *Nature* 2009;461:399-401.
7. Suppiah V, Moldovan M, Ahlenstiel G, et al. *IL28B* is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 2009;41:1100-1104.
8. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of *IL28B* with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009;41:1105-1109.
9. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 2009;360:1839-1850.
10. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. *Lancet* 2010;376:705-716.
11. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 2009;360:1827-1838.
12. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. *N Engl J Med* 2010;362:1292-1303.
13. Berg T, McHutchison JG, Adda N, et al. SVR with telaprevir, peginterferon alfa-2a and ribavirin in HCV patients with well-characterized prior null-response, partial response, viral breakthrough or relapse after PR. *J Hepatol* 2010;52(Suppl 1):S2.
14. Jacobson IM, McHutchison JG, Dusheiko GM, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: final results of Phase 3 ADVANCE study. *Hepatology* 2010;52(Suppl):427A.
15. Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous nonresponders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin. *Hepatology* 2010;52 (Suppl):430A.
16. Poordad F, McCone J, Bacon BR, et al. Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naïve patients with hepatitis C virus (HCV) genotype 1: SPRINT-2 final results. *Hepatology* 2010;52(Suppl):402A.
17. Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of Phase 3 ILLUMINATE study. *Hepatology* 2010;52(Suppl):401A.

18. Pawlotsky JM. Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus. *Hepatology* 2011;53: 1742–1751.
19. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology* 2010;138: 1338–1345.
20. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. *Gastroenterology* 2010;138: 2307–2314.
21. Chevaliez S, Bouvier-Alias M, Brillet R, et al. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. *Hepatology* 2007;46:22–31.
22. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. *Gastroenterology* 2010; 139:1593–1601.
23. Lotrich FE, Loftis JM, Ferrell RE, et al. IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. *J Interferon Cytokine Res* 2010 Dec 6. [Epub ahead of print].
24. Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. *Ann Intern Med* 2009; 150:528–540.
25. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. *Gastroenterology* 2009;136:1618–1628 e2.
26. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. *Gastroenterology* 2004;126:1015–1023.
27. Taliani G, Gemignani G, Ferrari C, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. *Gastroenterology* 2006;130:1098–1106.
28. Neumann A, Bibert S, Haagmans B, et al. IL28B polymorphism is significantly correlated with IFN antiviral effectiveness already on first day of pegylated interferon alpha and ribavirin therapy of chronic HCV infection. *J Hepatol* 2010;52(Suppl 1):S468.

Received November 20, 2010. Accepted March 8, 2011.

Reprint requests

Address requests for reprints to: Jean-Michel Pawlotsky, MD, PhD, Department of Virology, Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France. e-mail: jean-michel.pawlotsky@hmn.aphp.fr; fax: +33-1-4981-4831.

Acknowledgments

The authors thank the patients and nurses for their involvement in the study.

Drs Chevaliez and Hézode contributed equally to this work.

Conflicts of interest

These authors disclose the following: Dr Chevaliez is an advisor for Roche. Dr Hézode is an advisor and paid lecturer for Roche. Dr Rouanet is an employee of Roche. Dr Bronowicki is an advisor and paid lecturer for Roche. Dr Tran is an advisor and paid lecturer for Roche. Dr Mathurin is an advisor and paid lecturer for Roche. Dr Alric is an advisor and paid lecturer for Roche. Dr Leroy is an advisor and paid lecturer for Roche. Dr Charaf-Eddine is an employee of Roche. Dr Babany is an employee of Roche. Dr Pawlotsky is an advisor and paid lecturer for Roche. The remaining authors disclose no conflicts.

Funding

This study is investigator-initiated. It has been funded by Roche France, which provided the study drugs.